PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19724024-0 2009 Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1. Rosuvastatin Calcium 0-12 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 85-90 33029491-8 2020 The analysis of expression profiles at both the RNA and protein levels, using real-time quantitative polymerase chain reaction and Western blot analysis, indicated that LDL-R/CD68/LOX-1-positive monocyte/macrophage-mediated enhanced proinflammatory activation, including the significant upregulation of tumor necrosis factor-alpha and interleukin-6, was actually attenuated by sarpogrelate and/or rosuvastatin treatment. Rosuvastatin Calcium 397-409 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 180-185 19724024-9 2009 Rosuvastatin also reduced Ang II-mediated upregulation of AT1R and LOX-1. Rosuvastatin Calcium 0-12 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 67-72 19724024-10 2009 In other experiments, LOX-1 was upregulated in cardiomyocytes by transfection with pCI-neo/LOX-1, which also enhanced the expression AT1R messenger RNA (mRNA), and rosuvastatin pretreatment reduced the expression of both LOX-1 and AT1R in this system. Rosuvastatin Calcium 164-176 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 22-27 19724024-10 2009 In other experiments, LOX-1 was upregulated in cardiomyocytes by transfection with pCI-neo/LOX-1, which also enhanced the expression AT1R messenger RNA (mRNA), and rosuvastatin pretreatment reduced the expression of both LOX-1 and AT1R in this system. Rosuvastatin Calcium 164-176 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 91-96 19724024-10 2009 In other experiments, LOX-1 was upregulated in cardiomyocytes by transfection with pCI-neo/LOX-1, which also enhanced the expression AT1R messenger RNA (mRNA), and rosuvastatin pretreatment reduced the expression of both LOX-1 and AT1R in this system. Rosuvastatin Calcium 164-176 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 91-96 19724024-11 2009 Thus, rosuvastatin attenuates Ang II-mediated cardiomyocyte growth by inhibiting LOX-1 and AT1R expression and suppressing the heightened intracellular redox state. Rosuvastatin Calcium 6-18 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 81-86 33093907-9 2020 Furthermore, sarpogrelate combined with rosuvastatin treatment significantly decreased the expression levels of LOX-1 and p-ERK. Rosuvastatin Calcium 40-52 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 112-117 33093907-10 2020 Taken together, these results suggest that the positive effects of sarpogrelate combined with rosuvastatin treatment on aortic injury may be associated with the regulation of the LOX-1/p-ERK signaling pathway. Rosuvastatin Calcium 94-106 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 179-184 19724024-3 2009 We postulated that rosuvastatin, a potent HMG-CoA reductase inhibitor, may reduce Ang II-mediated cardiomyocyte growth via AT1R and LOX-1 inhibition. Rosuvastatin Calcium 19-31 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 132-137 19687748-8 2009 Administration of rosuvastatin or amlodipine reduced the overexpression of genes for LOX-1 and AT1R and associated NADPH oxidase and NF-kappaB. Rosuvastatin Calcium 18-30 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 85-90 16005008-10 2006 While rosuvastatin and candesartan each had a small inhibitory effect on the expression of LOX-1 in the atherosclerotic tissues, the combination totally blocked the up-regulation of LOX-1. Rosuvastatin Calcium 6-18 oxidized low density lipoprotein (lectin-like) receptor 1 Mus musculus 91-96